Related Experiment Video
Updated: May 6, 2026
12:01
Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein
Published on: May 30, 2015
10.5K
Tonsillar Alpha-Synuclein Accumulation on Parkinson's Disease
Cansu Sarıkaya1, Sebla Çalışkan2, Özkan Özdemir3
1Department of Neurology, Bahçeşehir University Medical Park Göztepe Hospital, İstanbul, Türkiye.
Noro Psikiyatri Arsivi
|March 4, 2026
Summary
Parkinson's disease (PD) patients exhibit elevated alpha-synuclein in tonsil tissue, suggesting tonsils may serve as a novel biomarker for this neurodegenerative disorder. This finding aids in early PD diagnosis and monitoring potential treatment efficacy.
Area of Science:
- Neuroscience
- Biomarker Discovery
- Pathology
Background:
- Parkinson's disease (PD) is characterized by alpha-synuclein protein misfolding.
- Current diagnostic methods for PD have limitations, with high misdiagnosis rates.
- The role of alpha-synuclein in lymphatic tissues like tonsils remains under-investigated.
Purpose of the Study:
- To investigate and compare alpha-synuclein levels in tonsillar tissues of PD patients and healthy controls.
- To evaluate the potential of tonsils as a site for alpha-synuclein deposition.
- To explore the utility of tonsil tissue as a potential biomarker for Parkinson's disease.
Main Methods:
- Tonsil tissue samples were collected from 11 PD patients and 15 healthy controls.
- Alpha-synuclein concentrations were quantified using Enzyme-Linked Immunosorbent Assay (ELISA).
- Statistical analysis involved Mann-Whitney U and Kolmogorov-Smirnov tests (p<0.05 significance).
Main Results:
- No significant differences in age or gender were observed between the PD and control groups.
- Significantly higher concentrations of alpha-synuclein were found in the tonsillar tissues of PD patients compared to controls.
Conclusions:
- Tonsillar tissue demonstrates potential as a novel peripheral biomarker for Parkinson's disease.
- This finding may reflect systemic alpha-synuclein accumulation in PD.
- Further research is warranted to elucidate the mechanisms of alpha-synuclein deposition in tonsils and its clinical implications.
Related Concept Videos
01:37Neural Regulation
34.8K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
34.8K
03:03Amyloid Fibrils
10.4K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
10.4K
01:15Parkinson's Disease: Overview
2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
01:23Alzheimer Disease ll: Pathophysiology
44
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
44
01:24Parkinson Disease l: Introduction
28
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of...
28
01:24Parkinson Disease ll: Pathophysiology
34
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
34